Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Dose Optimization in ER+ Breast Cancer
NCT02483871Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of rosuvastatin in breast cancer (2 arms), sponsored by Duke University. Primary endpoints: Safety by adverse event at 16 weeks and Maximum tolerated dose at 16 weeks. Planned start Oct 2015; status: withdrawn.
02
Drugs
rosuvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02483871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483871.